Diabetes is a chronic metabolic disease caused by hyperglycemia due to a deficiency in insulin production or utilization,leading to multi-organ damage and high morbidity and mortality.Despite the multiple therapeutic ...Diabetes is a chronic metabolic disease caused by hyperglycemia due to a deficiency in insulin production or utilization,leading to multi-organ damage and high morbidity and mortality.Despite the multiple therapeutic options available,diabetes remains a leading cause of death,highlighting the continuing need for new diabetes management options.This study evaluates the Sechium H38707 hybrid,which,through its polyphenols content,can exert hypoglycemic,nephroprotective,hepatoprotective,and cardioprotective activities in a murine model of diabetes.Diabetes was induced by a single injection of streptozotocin(STZ,150 mg/kg).Sechium H38707(8,50,125,and 250 mg/kg)and glibenclamide(50 mg/kg)were administered daily by gavage after diabetes induction.This study demonstrates,in a streptozotocin-induced diabetic mouse model,that the administration of the methanolic extract of the fruit of the Sechium H38707 hybrid acts as a hypoglycemic agent by reducing blood glucose levels,HbA1c,insulin,and insulin resistance.Additionally,it regulates lipid control levels and reduces cardiovascular and atherogenic risk with values similar to the drug glibenclamide.Sechium H38707 also improves parameters of the hepatic,renal,and pancreatic profile,as reflected by the histological preservation of the islets of Langerhans,hepatocytes,and renal glomeruli.Therefore,the methanolic extract of the Sechium H38707 hybrid functions as a phytopharmaceutical for the control of diabetes and its metabolic complications.展开更多
基金supported by grants from the General Directorate of Academic Personnel Affairs,National Autonomous University of Mexico(DGAPA-UNAM,PAPIIT-IA205222 and IA205324).
文摘Diabetes is a chronic metabolic disease caused by hyperglycemia due to a deficiency in insulin production or utilization,leading to multi-organ damage and high morbidity and mortality.Despite the multiple therapeutic options available,diabetes remains a leading cause of death,highlighting the continuing need for new diabetes management options.This study evaluates the Sechium H38707 hybrid,which,through its polyphenols content,can exert hypoglycemic,nephroprotective,hepatoprotective,and cardioprotective activities in a murine model of diabetes.Diabetes was induced by a single injection of streptozotocin(STZ,150 mg/kg).Sechium H38707(8,50,125,and 250 mg/kg)and glibenclamide(50 mg/kg)were administered daily by gavage after diabetes induction.This study demonstrates,in a streptozotocin-induced diabetic mouse model,that the administration of the methanolic extract of the fruit of the Sechium H38707 hybrid acts as a hypoglycemic agent by reducing blood glucose levels,HbA1c,insulin,and insulin resistance.Additionally,it regulates lipid control levels and reduces cardiovascular and atherogenic risk with values similar to the drug glibenclamide.Sechium H38707 also improves parameters of the hepatic,renal,and pancreatic profile,as reflected by the histological preservation of the islets of Langerhans,hepatocytes,and renal glomeruli.Therefore,the methanolic extract of the Sechium H38707 hybrid functions as a phytopharmaceutical for the control of diabetes and its metabolic complications.
